Can immunotherapy let doctors dial down cancer treatment without sacrificing cures?
NCT ID NCT04988074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether giving the immunotherapy drug cemiplimab (sometimes with chemotherapy) before standard treatment can shrink tumors enough to allow less intense local therapy, such as reduced radiation or surgery. The goal is to maintain high cure rates while improving long-term quality of life, especially swallowing function. The study enrolls 32 people with advanced HPV-related head and neck cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (a cancer immunotherapy drug, also known as Libtayo), sometimes combined with chemotherapy drugs carboplatin and paclitaxel
What this could lead to
If successful, this approach could allow some patients with advanced HPV-related head and neck cancer to receive less intense local treatments (like radiation or surgery), reducing side effects while still achieving high cure rates.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The immunotherapy may not shrink tumors enough to safely reduce treatment, and side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••